QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 whats-going-on-sarepta-stock-on-wednesday

Sarepta prepares to present new data on Duchenne and limb-girdle muscular dystrophy gene therapy programs this week.

 taysha-gene-therapies-canaan-ondas-holdings-and-other-big-stocks-moving-higher-on-thursday

U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday.

 watching-sarepta-therapeutics-shares-are-moving-higher-traders-circulate-linkedin-post-from-us-fda-drug-regulator-george-tidmarsh

https://www.linkedin.com/posts/george-f-tidmarsh-972061b_cder-will-be-evaluating-surrogate-endpoints-activity-73783970832230563...

 bmo-capital-upgrades-sarepta-therapeutics-to-outperform-maintains-price-target-to-50

BMO Capital analyst Kostas Biliouris upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Market Perform to Outperform and maint...

 guggenheim-reiterates-buy-on-sarepta-therapeutics-maintains-22-price-target

Guggenheim analyst Debjit Chattopadhyay reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and maintains $22 price tar...

 leerink-partners-maintains-market-perform-on-sarepta-therapeutics-raises-price-target-to-15

Leerink Partners analyst Joseph Schwartz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Market Perform and raises the p...

Core News & Articles

https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250826-1479707/1479707_brkl6.pdf

 hc-wainwright--co-reiterates-sell-on-sarepta-therapeutics-maintains-5-price-target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $...

 b-of-a-securities-maintains-underperform-on-sarepta-therapeutics-lowers-price-target-to-16

B of A Securities analyst Tazeen Ahmad maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Underperform and lowers the price...

 b-of-a-securities-maintains-underperform-on-sarepta-therapeutics-raises-price-target-to-17

B of A Securities analyst Tazeen Ahmad maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Underperform and raises the price...

 deutsche-bank-maintains-sell-on-sarepta-therapeutics-raises-price-target-to-12

Deutsche Bank analyst David Hoang maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and raises the price target from ...

Core News & Articles

- Arrowhead has elected to receive approximately $50 million worth of Arrowhead common stock from Sarepta, which will be placed...

 vinay-prasads-comeback-to-fda-sparks-debate-over-regulatory-direction

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vac...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION